Rhumbline Advisers lifted its stake in Nuvectra Corp (NASDAQ:NVTR) by 12.6% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,325 shares of the company’s stock after purchasing an additional 2,502 shares during the period. Rhumbline Advisers owned 0.13% of Nuvectra worth $246,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of NVTR. BNP Paribas Arbitrage SA bought a new position in shares of Nuvectra in the 1st quarter worth $40,000. PNC Financial Services Group Inc. boosted its position in shares of Nuvectra by 231.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,318 shares of the company’s stock worth $54,000 after purchasing an additional 2,318 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in shares of Nuvectra by 356.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,108 shares of the company’s stock worth $83,000 after purchasing an additional 3,989 shares during the last quarter. American International Group Inc. boosted its position in shares of Nuvectra by 23.5% in the 4th quarter. American International Group Inc. now owns 11,394 shares of the company’s stock worth $186,000 after purchasing an additional 2,166 shares during the last quarter. Finally, Edge Wealth Management LLC boosted its position in shares of Nuvectra by 88.1% in the 1st quarter. Edge Wealth Management LLC now owns 21,140 shares of the company’s stock worth $235,000 after purchasing an additional 9,900 shares during the last quarter. Institutional investors and hedge funds own 81.14% of the company’s stock.
NVTR has been the topic of several recent research reports. BidaskClub upgraded Nuvectra from a “sell” rating to a “hold” rating in a research report on Wednesday, February 20th. Raymond James reduced their price target on Nuvectra from $23.00 to $18.00 and set an “outperform” rating on the stock in a research report on Friday, March 1st. ValuEngine lowered Nuvectra from a “hold” rating to a “sell” rating in a research report on Friday, May 3rd. Finally, JMP Securities reduced their price target on Nuvectra from $26.00 to $18.00 and set an “outperform” rating on the stock in a research report on Thursday, May 2nd. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. Nuvectra presently has an average rating of “Hold” and a consensus target price of $20.40.
Shares of Nuvectra stock opened at $3.95 on Friday. The firm has a market cap of $65.15 million, a P/E ratio of -1.24 and a beta of 1.00. Nuvectra Corp has a 12 month low of $3.48 and a 12 month high of $25.17. The company has a debt-to-equity ratio of 0.56, a quick ratio of 6.07 and a current ratio of 6.60.
Nuvectra (NASDAQ:NVTR) last issued its quarterly earnings data on Wednesday, May 1st. The company reported ($0.83) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.18). The business had revenue of $11.13 million for the quarter, compared to analyst estimates of $12.76 million. Nuvectra had a negative return on equity of 62.18% and a negative net margin of 98.77%. On average, analysts expect that Nuvectra Corp will post -3.17 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Rhumbline Advisers Buys 2,502 Shares of Nuvectra Corp (NASDAQ:NVTR)” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://sportsperspectives.com/2019/06/14/rhumbline-advisers-buys-2502-shares-of-nuvectra-corp-nasdaqnvtr.html.
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.
See Also: What is the Rule of 72?
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.